Eisai Cuts Full-Year Profit Forecast 20% as Aricept Sales Drop

Eisai Co. cut its full-year net income forecast by 20 percent because of lower-than-expected sales of the Aricept drug for Alzheimer’s disease, the company’s biggest earnings contributor.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.